Guggenheim analyst Subbu Nambi raised the firm’s price target on Bruker (BRKR) to $53 from $45 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for its covered Diagnostics and Life Sciences Tools companies to reflect recent updates from the companies after meetings with management teams.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- RI Research secures orders for enabling subsystems for gamma ray source of ELI
- AbCellera to receive $36M upfront in patent litigation settlement with Bruker
- Bruker price target raised to $60 from $43 at BofA
- Bruker price target raised to $55 from $50 at JPMorgan
- Bruker Receives Buy Rating Amid Strong Financial Outlook and Margin Expansion Plans